Tag Archives: ABBV-295

Arrowhead Q3 ’26 Earnings; Lilly Breaks Ground on US Manufacturing Facility; Tandem Mobi Tubeless FDA Clearance; November CHMP Highlights; AbbVie Skyrizi + Amylin Combo PsO Study; Vivani Topline Ph1 Sema Implant Data

A series of cardiometabolic-related news items has been observed from Arrowhead Pharmaceuticals, Lilly, Tandem Diabetes Care, EMA, AbbVie, and Vivani Medical. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

EASD 2026 Key Press Releases (September 30 Part 2)

On the third day of EASD 2026, four key news items were observed in the afternoon from Lilly, AbbVie, Kailera Therapeutics, and Insilico Medicine. Below, FENIX provides context and analysis for the announcements.

This content is for Read Less members only.
Already a member? Log in here

EASD 2026 Preview: Where FENIX will be paying attention and why

With EASD 2026 approaching (September 28-October 2; Milan, Italy), FENIX has compiled a short list of key sessions and presentations that warrant close attention. While EASD brings new data and fresh perspectives across the cardiometabolic space each year, the list below focuses exclusively on the sessions with potential to shape this year’s conference narrative and ultimately have an outsized impact on the field for years to come.

This content is for Read Less members only.
Already a member? Log in here

Gubra Receives Milestone Payment from AbbVie; Caliway Advances Lipolysis Drug

Two cardiometabolic-related news items have been observed: Gubra received a $50M milestone payment from AbbVie (view press release), and Caliway Biopharmaceuticals received IND clearance and IRB approval for its small molecule lipolysis drug (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Novo and Hims Take Another Turn at a Partnership; AbbVie Reports Topline Ph1 Amylin Data; Regeneron & Hansoh Share Ph3 Olatorepatide China Results; Lilly Releases Statement on CMS Obesity BALANCE Model; Zepbound KwikPen Available on Amazon; Veru Enrolls First Patient in Ph2b PLATEAU Study; Sequel Expands AID Launch 

A series of cardiometabolic-related news items has been observed from Novo Nordisk/Hims & Hers, AbbVie, Regeneron Pharmaceuticals/Hansoh, Lilly, Amazon, Veru, and Sequel Med Tech. Below, FENIX provides highlights and insights into the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Hims Launches Compounded Sema Pill; Novo London, AbbVie, GSK, and Novartis Q4 ’25 Earnings; Stelo Smart Meal Logging Updates; Abbott FDA Warning Letter and Class I Recall; Rare Pediatric PRV Program Reauthorized; Sciwind Ph3 OSA Study

A series of cardiometabolic-related news items has been observed from Hims & Hers, Novo Nordisk, AbbVie, GSK, Novartis, Dexcom, Abbott, the White House, and Sciwind Biosciences. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

JPM 2026 Day 3: ZLDPF, ABBV, SANA, PODD; Jazz to Sell PRV; Novo Initiates Amycretin Ph3 Program; Madrigal Initiates New Ph2 Resmetirom MASH Study; Sandoz Confirms EC Approval of Ondibta

On the third day of JPM 2026, FENIX has provided coverage of presentations by major CVRM companies, including Zealand, AbbVie, Sana Biotechnology, and Insulet. Separately, a series of CVRM-related news items has been observed. Below, FENIX provides highlights and insights for the respective news items, including speculation into who purchased Jazz’s PRV.

This content is for Read Less members only.
Already a member? Log in here